Jasper Therapeutics (Jasper Therapeutics) Additional Paid-In Capital : $296.56 Mil(As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Jasper Therapeutics Additional Paid-In Capital?

Jasper Therapeutics's quarterly additional paid-in capital increased from Sep. 2023 ($247.14 Mil) to Dec. 2023 ($248.04 Mil) and increased from Dec. 2023 ($248.04 Mil) to Mar. 2024 ($296.56 Mil).

Jasper Therapeutics's annual additional paid-in capital increased from Dec. 2021 ($136.96 Mil) to Dec. 2022 ($141.12 Mil) and increased from Dec. 2022 ($141.12 Mil) to Dec. 2023 ($248.04 Mil).

Jasper Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Jasper Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jasper Therapeutics Additional Paid-In Capital Chart

Jasper Therapeutics Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

1.68

136.96

141.12

248.04

Jasper Therapeutics Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial										244.58	245.67	247.14	248.04	296.56

Jasper Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Jasper Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Jasper Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Jasper Therapeutics (Jasper Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Jasper Therapeutics Inc (NAS:JSPR) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

N/A

Address

2200 Bridge Parkway, Suite No. 102, Redwood, CA, USA, 94065

Website

https://www.jaspertherapeutics.com

Jasper Therapeutics Inc is a clinical-stage biotechnology company dedicated to enabling cures through hematopoietic stem cell therapy. It is focused on the development and commercialization of safer and more effective conditioning agents and stem cell engineering to allow for expanded use of stem cell transplantation and ex vivo gene therapy.

Executives

Thomas G Wiggans	director
William Lis	director	PORTOLA PHARMACEUTICALS, INC., 270 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Jeetinder Singh Mahal	officer: Chief Operating Officer	C/O JASPER THERAPEUTICS, INC., 2200 BRIDGE PARKWAY, SUITE 102, REDWOOD CITY CA 94065
Ron Martell	director, officer: President, CEO & Director	PONIARD PHARMACEUTICALS, INC., 750 BATTERY STREET, SUITE 330, SAN FRANCISCO CA 94111
Herb Cross	officer: Chief Financial Officer	3061 ZANKER RD, SAN JOSE CA 95134
Scott C. Brun	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Edwin Jonathan Tucker	officer: Chief Medical Officer	C/O MIRUM PHARMACEUTICALS, INC., 950 TOWER LANE, SUITE 1050, FOSTER CITY CA 94404
Anna Louise French	director	C/O QIMING U.S. HEALTHCARE, 11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Kurt Von Emster	director, 10 percent owner	601 GATEWAY BOULEVARD, SUITE 350, SAN FRANCISCO CA 94080
Gary E Rieschel	10 percent owner
Qiming U.s. Healthcare Fund Ii, L.p.	10 percent owner	350 106TH AVENUE NE, 1ST FLOOR, BELLEVUE WA 98004
Llp Abingworth	10 percent owner	38 JERMYN STREET, LONDON X0 SW1Y 6DN
Mark Mcdade	10 percent owner	C/O PROTINE DESIGN LAB, 7442 NORTH MARCER WAY, MERCER ISLAND WA 98040
Qiming U.s. Healthcare Gp Ii, Llc	10 percent owner	11100 NE 8TH ST, SUITE 200, BELLEVUE WA 98004
Carlyle Group Inc.	10 percent owner	C/O THE CARLYLE GROUP, 1001 PENNSYLVANIA AVENUE, N.W., WASHINGTON DC 20004